Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Astria Therapeutics (NASDAQ:ATXS) has announced its upcoming presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Scientific Session in Waimea, Hawaii, scheduled for February 9-13, 2025.
The presentation will focus on quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215). Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at UC San Diego, will present an encore poster titled 'Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial.'
The poster will be on display from 3:00pm ET on February 9 through February 13, 2025.
Astria Therapeutics (NASDAQ:ATXS) ha annunciato la sua prossima presentazione presso il Congress Annuale della Western Society of Allergy, Asthma & Immunology (WSAAI), che si terrà a Waimea, Hawaii, dal 9 al 13 febbraio 2025.
La presentazione si concentrerà sui risultati di qualità della vita del trial di Fase 1b/2 di navenibart (STAR-0215). Il Dott. Marc A. Riedl, Professore di Medicina e Direttore Clinico del Centro HAEA Angioedema negli Stati Uniti presso l'UC San Diego, presenterà un poster intitolato 'Navenibart (STAR-0215) Induce Miglioramenti Rapidi della Qualità della Vita nei Pazienti con HAE nel Trial ALPHA-STAR.'
Il poster sarà esposto dalle 15:00 ET del 9 febbraio fino al 13 febbraio 2025.
Astria Therapeutics (NASDAQ:ATXS) ha anunciado su próxima presentación en la Sesión Científica Anual de la Western Society of Allergy, Asthma & Immunology (WSAAI) en Waimea, Hawái, programada para el 9-13 de febrero de 2025.
La presentación se centrará en los resultados de calidad de vida del ensayo de Fase 1b/2 de navenibart (STAR-0215). El Dr. Marc A. Riedl, Profesor de Medicina y Director Clínico del Centro HAEA de Angioedema en UC San Diego, presentará un póster titulado 'Navenibart (STAR-0215) Induce Mejoras Rápidas en la Calidad de Vida de Pacientes con HAE en el Ensayo ALPHA-STAR.'
El póster estará en exhibición desde las 3:00pm ET del 9 de febrero hasta el 13 de febrero de 2025.
Astria Therapeutics (NASDAQ:ATXS)는 2025년 2월 9일부터 13일까지 하와이 와이메이에서 열리는 서부 알레르기, 천식 및 면역학회(WSAAI) 연례 과학 세션에서 발표할 예정이라고 발표했다.
이번 발표는 navenibart (STAR-0215)의 1b/2상 시험에서의 생활 질 결과에 초점을 맞출 것이다. UC 샌디에이고 HAEA Angioedema 센터의 의학 교수이자 임상 책임자인 마르크 A. 리들 박사(Dr. Marc A. Riedl)는 'Navenibart (STAR-0215)가 ALPHA-STAR 시험에서 HAE 환자의 생활 질을 빠르게 개선한다'라는 제목의 포스터를 발표할 예정이다.
포스터는 2025년 2월 9일 오후 3시 ET부터 2월 13일까지 전시된다.
Astria Therapeutics (NASDAQ:ATXS) a annoncé sa prochaine présentation lors de la Session Scientifique Annuelle de la Western Society of Allergy, Asthma & Immunology (WSAAI), qui se tiendra à Waimea, Hawaii, du 9 au 13 février 2025.
La présentation se concentrera sur les résultats de qualité de vie de l'essai de Phase 1b/2 de navenibart (STAR-0215). Dr. Marc A. Riedl, Professeur de Médecine et Directeur Clinique du Centre HAEA d'Angioedème aux États-Unis à l'UC San Diego, présentera un poster intitulé 'Navenibart (STAR-0215) Induit des Améliorations Rapides de la Qualité de Vie chez les Patients HAE lors de l'Essai ALPHA-STAR.'
Le poster sera exposé de 15h00 ET le 9 février jusqu'au 13 février 2025.
Astria Therapeutics (NASDAQ:ATXS) hat seine bevorstehende Präsentation bei der Jahrestagung der Western Society of Allergy, Asthma & Immunology (WSAAI) in Waimea, Hawaii, angekündigt, die vom 9. bis 13. Februar 2025 stattfindet.
Die Präsentation wird sich auf die Lebensqualitätsdaten aus der Phase 1b/2-Studie von navenibart (STAR-0215) konzentrieren. Dr. Marc A. Riedl, Professor für Medizin und Klinischer Direktor des US HAEA Angioedema Centers an der UC San Diego, wird ein Nachfolge-Poster mit dem Titel 'Navenibart (STAR-0215) Führt zu Schnellen Verbesserungen der Lebensqualität bei HAE-Patienten in der ALPHA-STAR-Studie' präsentieren.
Das Poster wird von 15:00 Uhr ET am 9. Februar bis zum 13. Februar 2025 ausgestellt.
- None.
- None.
Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203211996/en/
Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
What are the key findings from Astria Therapeutics' ALPHA-STAR trial for navenibart (STAR-0215)?
When and where will Astria Therapeutics (ATXS) present their navenibart trial results in 2025?
What is the focus of Astria Therapeutics' (ATXS) Phase 1b/2 navenibart trial presentation?
Who will present Astria Therapeutics' (ATXS) navenibart trial results at WSAAI 2025?
